Evidence map›Paper›PMID 41723132›Full record

ArticleNature communications2026

Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.

Maryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, Ziyang Su, Anthony Cornu, Tania Wyss, Burak Kizil, Robert Pick, Katayoun Falamaki, Pratyaksha Wirapati and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Maryline FalquetDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-5940-8583
Hajar El Ahanidi *Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Alejandra Gomez-Cadena *Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Ziyang SuDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Anthony CornuDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0009-0005-2477-0020
Tania WyssTranslational Data Science Facility, AGORA Cancer Research Center, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2641-0895
Burak KizilDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Robert PickDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-9785-8481
Katayoun FalamakiDepartment of Internal Medicine Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pratyaksha WirapatiDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-0327-4686
Benedetta FiordiDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Isis SenonerDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Daniela Claudia MarescaDepartment of Pharmacy, University Federico II of Naples Italy, Naples, Italy.ORCID http://orcid.org/0009-0008-4221-6375
Neil KallalDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0009-0001-4299-2699
Danaé GuedjDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0009-0004-2539-6432
Mario KreutzfeldtDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-0335-2733
Jean-Christophe TilleDepartment of Diagnostics, Division of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.
Marine M LeblondLudwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.
Katarzyna MichaudUniversity Centre of Legal Medicine Lausanne-Geneva, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Silvia PesceDepartment of Experimental Medicine, University of Genova, Genova, Italy.
Simona CandianiRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Korneliusz GolebskiDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Julien DagherInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Melinda CharrierDepartment of Oncology, Precision Oncology Service, University Hospital of Geneva, Geneva, Switzerland.
Caroline Pressacco BrossierDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Elisabeth Grobet-JeandinDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Romina MaroneDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-1474-1689
Stéphanie HuguesDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Lukas T JekerDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3359-8796
Grégory VerdeilLudwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-9445-8474
Doron MerklerDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-0247-2007
Emanuela MarcenaroDepartment of Experimental Medicine, University of Genova, Genova, Italy.ORCID http://orcid.org/0000-0003-4103-7566
Christoph ScheiermannDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-9212-0995
Mohammed AttalebCentre National de l'Energie, des Sciences et Techniques nucléaires (CNESTEN), Rabat, Morocco.
Daniel BenamranDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Petros TsantoulisTranslational Research Centre in Onco-Hematology (CRTOH), Geneva, Switzerland.ORCID http://orcid.org/0000-0003-3613-6682
Giuseppe ErcolanoDepartment of Pharmacy, University Federico II of Naples Italy, Naples, Italy.ORCID http://orcid.org/0000-0001-6026-2588
Sara TrabanelliDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-8648-1324
Camilla JandusDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Camilla.jandus@unige.ch.ORCID http://orcid.org/0000-0002-7405-5747

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 818806Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) MD-PhD fellowshipSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) PRIMA PR00P3_179727Université de Genève (University of Geneva) INNOGAP
6 · The paper itself

Abstract

Innate lymphoid cells type 2 (ILC2s) are key regulators of tissue homeostasis and inflammation. In cancer, ILC2s can exhibit pro-tumoral functions by increasing the myeloid derived suppressor cells (MDSC)/T-cell ratio. Nevertheless, the upstream ILC2 triggers remain poorly defined. Here, we identify nerve growth factor (NGF) as the driver of ILC2 pro-tumoral functions in patients with bladder cancer. We show that ILC2s express the NGF receptor TrkA and respond to NGF by secreting type-2 cytokines. In the tumor microenvironment, NGF-producing mast cells accumulate and activate ILC2s to induce regulatory T cells (Tregs), ultimately fostering tumor growth. In patients, NGF levels inversely correlate with survival in ILC2-rich tumors, underscoring the clinical significance of this axis. In vivo administration of a selective TrkA inhibitor improves survival in orthotopic tumor-bearing female mice and sensitizes them to immune checkpoint blockade (ICB). Overall, we identify NGF as an ILC2 activator that shapes pro-tumoral ILC2 functions. The blockade of TrkA

Indexed as

Immunity, InnateLymphocytesMast CellsNerve Growth FactorUrinary Bladder NeoplasmsAnimalsCell Line, TumorCytokinesFemaleHumansMaleMiceMice, Inbred C57BLReceptor, trkAT-Lymphocytes, RegulatoryTumor MicroenvironmentCytokinesNerve Growth FactorNGF protein, humanNTRK1 protein, humanReceptor, trkA

Identifiers

PMID41723132
PMCPMC13039139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.